Rachna T Shroff, MD, MS, FASCO

-
Associate Director of Clinical Investigations, University of Arizona Cancer Center (UACC)
Associate Dean, Clinical and Translational Research
Chief, Division of Hematology/Oncology
Professor of Medicine - (Tenured)
Biography
Rachna T. Shroff, MD, MS, FASCO, is associate director of Clinical Investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She also is a professor with tenure in the Department of Medicine, interim chief of the Division of Hematology and Oncology, Medical Director for the Oncology Service Line, and associate dean for Clinical and Translational Research for the University of Arizona College of Medicine – Tucson. She came to UACC from MD Anderson Cancer Center in Houston, where she was on faculty from 2010-18 after completing her medical oncology fellowship there.
Cancer Focus
Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary Subcommittee co-chair for the Southwest Oncology Group (SWOG) and as Chair for GI ASCO 2024, a meeting sponsored by the American Society of Clinical Oncology focused on gastrointestinal cancers. Most recently, she was elected to serve on the ASCO Nominating Committee. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation.
Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.
Selected Publications
Mizrahi, J. D., R. Surana, J. W. Valle, and R. T. Shroff, "Pancreatic cancer.", Lancet, vol. 395, issue 10242, pp. 2008-2020, 2020 06 27. PMID: 32593337
Shroff, R. T., E. B. Kennedy, M. Bachini, T. Bekaii-Saab, C. Crane, J. Edeline, A. El-Khoueiry, M. Feng, M. H. G. Katz, J. Primrose, et al., "Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.", J Clin Oncol, vol. 37, issue 12, pp. 1015-1027, 2019 04 20. PMID: 30856044
Shroff, R. T., A. Hendifar, R. R. McWilliams, R. Geva, R. Epelbaum, L. Rolfe, S. Goble, K. K. Lin, A. V. Biankin, H. Giordano, et al., "Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious Mutation.", JCO Precis Oncol, vol. 2018, 2018. PMCID: PMC6057747 PMID: 30051098
Javle, M., M. Lowery, R. T. Shroff, K. Heinz Weiss, C. Springfeld, M. J. Borad, R. K. Ramanathan, L. Goyal, S. Sadeghi, T. Macarulla, et al., "Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.", J Clin Oncol, vol. 36, issue 3, pp. 276-282, 2018 Jan 20. PMCID: PMC6075847 PMID: 29182496
Shroff, R. T., M. Yarchoan, A. O'Connor, D. Gallagher, M. L. Zahurak, G. Rosner, C. Ohaji, S. Sartorius-Mergenthaler, R. Parkinson, V. Subbiah, et al., "The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.", Br J Cancer, vol. 118, issue 2, pp. e2, 2018 01. PMCID: PMC5785753 PMID: 29315294
Rogers, J. E., R. M. Bolonesi, A. Rashid, K. M. Elsayes, M. G. Elbanan, L. Law, A. Kaseb, and R. T. Shroff, "Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.", J Gastrointest Oncol, vol. 8, issue 2, pp. 347-351, 2017 Apr. PMCID: PMC5401851 PMID: 28480073
"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.", Cancer Cell, vol. 32, issue 2, pp. 185-203.e13, 2017 08 14. PMCID: PMC5964983 PMID: 28810144
Shroff, R. T., J. Knox, and E. Dixon, "Consensus conference on gallbladder cancer.", HPB (Oxford), vol. 17, issue 8, pp. 664-5, 2015 Aug. PMCID: PMC4527850 PMID: 26172132